KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 March 2024 - 10:30PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted seven newly-hired employees inducement options to purchase
an aggregate of 43,000 shares of KalVista common stock on March 1,
2024 as inducements material to each employee entering into
employment with KalVista. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $14.14 per share, which
was equal to the closing price of KalVista common stock on the
grant date. One-fourth of the options vest on the one-year
anniversary of the vesting commencement date and the remainder vest
in equal monthly installments over the next three years, in each
case subject to the new employee’s continued service with the
company. Each stock option has a 10-year term and is subject to the
terms and conditions of KalVista’s Inducement Equity Incentive Plan
and a stock option agreement covering the grant.
About KalVista Pharmaceuticals, Inc. KalVista
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of oral, small
molecule protease inhibitors for diseases with significant unmet
need. KalVista disclosed positive phase 3 data for the KONFIDENT
trial for its oral, on-demand therapy sebetralstat in February
2024. The Company anticipates submitting a new drug application to
the U.S. FDA for sebetralstat in the first half of 2024 and expects
to file for approval in Europe and Japan later in 2024. In
addition, KalVista’s oral Factor XIIa inhibitor program represents
a new generation of therapies that may further improve the
treatment for people living with HAE and other diseases.
For more information about KalVista, please visit
www.kalvista.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240304835396/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024